News | Heart Valve Technology | February 22, 2018

Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation

Patient was discharged to home in a few days

Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation

February 22, 2018 — NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent bioprosthesis became the first Canadian orthotopic valve replacement to treat severe tricuspid regurgitation. The procedure was performed at the Quebec Heart and Lung Institute, Laval University (Quebec City, Canada) by the Institute’s Cardiac Team, led by Josep Rodés-Cabau, M.D., interventional cardiologist, an internationally known expert in tricuspid disease therapy; and François Dagenais, M.D., chief of cardiac surgery at the institute. They performed the Health Canada-sanctioned Expanded Access (Compassionate Use) procedure in the patient who presented with severe symptomatic tricuspid regurgitation.

The patient, a 79-year old male, was deemed at high-risk for standard cardiac surgery and unable to withstand cardiopulmonary external circulation. Rodés-Cabau, who has performed multiple procedures for atrioventricular valve dysfunction using various repair devices, said: “The NaviGate bioprosthesis is the only transcatheter device in development that has been used to completely replace the native tricuspid valve and restore its function in the human.” Rodés-Cabau proposed the NCSI Gate as the only viable treatment option for this patient.  The replacement procedure, performed in less than 30 minutes after the patient was prepared, minimized fluoroscopic exposure to both patient and operator, as well as contrast imaging media quantity known to be deleterious to the patient’s kidney.  

There were no immediate complications and an excellent result was obtained, which allowed the patient to be discharged within a few days after a satisfactory recovery from the procedure.  The patient said that for a long time before this procedure, he had experienced loss of balance and generalized weakness. Now, with feelings of relief a few days after the procedure, he felt much better and all was returning to normal.

In three of 10 previously treated patients, the Gate bioprostheses were implanted through the jugular vein of the neck through a tiny puncture.  “Because the patient’s anatomy did not allow jugular access to the tricuspid valve,” Dagenais explained, “we chose an alternate path.  Fortunately, with a small incision between a pair of right ribs, a direct path for the catheter led to quick implantation of the replacement valve. We must understand that the technology will evolve and soon the great majority of patients will receive their replacement valve through the neck veins,” he concluded.

Élisabeth Bédard, M.D., the cardiologist aiding the navigation through imaging, explained: “We see these patients continuously, showing edema of their lower limbs, shortness of breath and their chests full of liquid. We give them medications to relieve them of some fluid but in a short time come to an end where we cannot help them anymore. Suddenly, we see a superb new technology that may help our patients.”

The patient now joins a cohort of 10 patients, seven with valves functioning over 5 months, and he joins in two weeks a cohort of three patients with well-functioning Gate bioprostheses that has reached greater than 30 days.  

The valve replacement system is developed at NaviGate Cardiac Structures Inc. and includes novel technology on tissue dehydration that extracts toxic fixative glutaraldehyde. That technology licensed from Cleveland Clinic Foundation’s original research and was co-licensed to Edwards Lifesciences from NCSI for fees and royalties. It is believed that such technology may have potential to increase the longevity of the tissue valvular mechanism.

The Gate atrioventricular valved stent is not approved for use in the U.S. The patient implants described in this news release were performed under compassionate pleas sanctioned by Health Canada, European Health agencies and the U.S. Food and Drug Administration (FDA).

For more information: www.navigatecsi.com

 

Related Content

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di
PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients undergoing transcatheter aortic valve repair (TAVR) low-risk patients at two years did just
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing t
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replace
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020
 
A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Image courtesy of TeraRecon

Feature | Heart Valve Technology | February 24, 2020 | Dave Fornell, Editor
In August 2019, the U.S.
Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

News | Heart Valve Technology | January 31, 2020
January 31, 2020 — A new study from the Sm...
Abbott Tendyne TMVR, TMVI system received European CE mark clearance in January 2020. The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. Prevents LVOT obstruction.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. The design also eliminated any hardware hanging or folding into the left ventricle, which could cause left ventricular outflow track (LVOT) obstruction, which can prevent blood flow through the aortic valve and to the rest of the body.

Feature | Heart Valve Technology | January 30, 2020
January 30, 2020 — The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received European CE mark
Overlay Init